

DESCRIPTION


Species Reactivity	Human
Specificity	Detects human CLEC10A/CD301 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human ASGPR1 or recombinant mouse MGL1 is observed.
Source	Monoclonal Mouse IgG _{2B} Clone # 744812
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human CLEC10A/CD301 Gln61-His316 Accession # Q8IUN9
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	5 µL/10 ⁶ cells	See Below

DATA



PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. ● 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

CLEC10A, also known as macrophage galactose/N-acetyl-galactosamine (GalNAc) specific lectin (MGL), CD301, DC-ASGPR, and HML, is a 40 kDa type II transmembrane glycoprotein that belongs to the C-type lectin family (1). Human and rat carry a single gene for CLEC10A/CD301, while mouse has two closely related MGL1 and MGL2 genes. Human CLEC10A/CD301 consists of a 39 amino acid (aa) cytoplasmic region, a 21 aa transmembrane segment and a 256 aa extracellular domain (ECD) with one carbohydrate recognition domain (CRD) and a neck region (2). Within the CRD, human CLEC10A/CD301 shares 64%-70% aa sequence identity with mouse MGL1, mouse MGL2, and rat MGL. Alternate splicing generates multiple isoforms of human CLEC10A/CD301 with 27 aa, 3 aa, and/or 4 aa deletions within the ECD (3, 4). CLEC10A/CD301 is expressed on immature myeloid dendritic cells and alternatively activated (tolerogenic) macrophages and is upregulated by the immunosuppressant dexamethasone (3-7). CLEC10A/CD301 selectively binds and internalizes terminal nonsialylated α - or β -linked GalNAc moieties on O-linked carbohydrates, including the Tn carcinoma antigen (2-4, 8, 9). Similar ligand preference is exhibited by mouse MGL2 but not MGL1 (10). CLEC10A/CD301 expressed on tolerogenic dendritic cells binds carbohydrate determinants on CD45 (RA, RB, and RC but not RO isoforms) expressed by T, NK, and B cells (6). This interaction inhibits effector T cell activation and induces their apoptosis (6). CLEC10A/CD301 also binds the GP envelope glycoprotein on Marburg and Ebola viruses and enhances viral entry and infectivity (11).

References:

1. Zelensky, A.N. and J.E. Gready (2005) *FEBS J.* **272**:6179.
2. Suzuki, N. *et al.* (1996) *J. Immunol.* **156**:128.
3. Higashi, N. *et al.* (2002) *J. Biol. Chem.* **277**:20686.
4. Valladeau, J. *et al.* (2001) *J. Immunol.* **167**:5767.
5. van Vliet, S.J. *et al.* (2006) *Immunobiology* **211**:577.
6. van Vliet, S.J. *et al.* (2006) *Nat. Immunol.* **7**:1200.
7. Raes, G. *et al.* (2005) *J. Leukoc. Biol.* **77**:321.
8. van Vliet, S.J. *et al.* (2005) *Int. Immunol.* **17**:661.
9. Higashi, N. *et al.* (2002) *Int. Immunol.* **14**:545.
10. Tsuiji, M. *et al.* (2002) *J. Biol. Chem.* **277**:28892.
11. Takada, A. *et al.* (2004) *J. Virol.* **78**:2943.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.